Jasper Zantvoord M.D., Ph.D., is a psychiatrist at Amsterdam UMC specialising in the treatment of severe mental disorders, with a primary focus on clinical trials evaluating novel pharmacological treatments and electroconvulsive therapy (ECT) for patients with treatment-resistant schizophrenia, bipolar disorder, and major depressive disorder.

Dr. Zantvoord has extensive experience in conducting investigator-initiated and industry-sponsored clinical trials, aiming to improve therapeutic options for patients who do not respond to standard treatments. In addition, in collaboration with the Dutch Medicines Evaluation Board, he actively conducts individual patient data (IPD) meta-analyses, utilising large datasets to refine treatment strategies and advance personalised psychiatry.

His research focuses on identifying patient-specific predictors of treatment response in both adolescents and adults, enabling a more tailored approach to pharmacological treatments. By integrating data-driven insights with clinical expertise, he aims to optimise treatment outcomes for individuals with severe psychiatric illnesses.

Currently, Jasper Zantvoord also serves as a member of the Institutional Review Board at Amsterdam UMC and serves as an external clinical and scientific expert at the European Medicines Agency (EMA) and Dutch Medicines Evaluation Board (CBG-MEB).